Taghon, G.
, Kapolka, N.
and Isom, D.
(2024),
Advances in Yeast Synthetic Biology for Human GPCR Biology and Pharmacology, Current Opinion in Biotechnology, [online], https://doi.org/10.1016/j.copbio.2024.103176, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=957792 (Accessed April 23, 2026)
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Advances in Yeast Synthetic Biology for Human GPCR Biology and Pharmacology
Published
Author(s)
, Nicholas Kapolka, Daniel Isom
Abstract
G protein-coupled receptors (GPCRs) are the largest family of transmembrane receptors in humans. Over 800 GPCRs regulate the (patho)biology of every organ, tissue, and cell type. Consequently, GPCRs are the most prominent therapeutic targets in medicine. Although over 30% of current FDA-approved drugs target GPCR signaling, most receptors remain understudied and therapeutically underutilized. Challenges include an incomplete understanding of GPCR signaling, pharmacology, structural biology, and the multiplicity of endogenous GPCR ligands, in addition to a scarcity of biological and pharmacological tools for elucidating GPCR-mediated cellular processes beyond initial signaling events. Various mammalian, insect, and yeast cell models currently address some of these needs. Here, we review recent advances in yeast synthetic biology that are helping to catalyze new and unexpected conceptual and technical breakthroughs in GPCR-based medicine and biotechnology.Citation
Current Opinion in Biotechnology
Volume
88
Pub Type
Journals
Download Paper
Keywords
GPCRs, synthetic biology, yeast, biosensors, screening
Citation
Issues
If you have any questions about this publication or are having problems accessing it, please contact [email protected].
Created July 29, 2024, Updated August 5, 2024